Chronos Archive seal
The Human Record

Gwen Ifill

Case HR-ML032 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
September 29, 1955 – November 14, 2016
Synthetic DOB
1965-09-29
Index visit
2026-01-05 at age 60
Synthetic MRN
HR-ML032-SYN

Teaching objective: Evaluate postmenopausal bleeding at once, as any bleeding after menopause requires, in a 60-year-old Black woman, whose risk of dying of endometrial cancer is about twice that of White women because of later diagnosis, more aggressive non-endometrioid and p53-abnormal tumors, and delays in evaluating bleeding: transvaginal ultrasound together with endometrial sampling at the first evaluation (the ACOG update that no longer relies on a thin endometrium alone); histology with the molecular classification (POLE, mismatch repair, p53) that the FIGO 2023 staging uses; CT staging; gynecologic oncology care with minimally invasive hysterectomy and sentinel lymph node mapping; treatment chosen by stage and molecular class, here dostarlimab with carboplatin and paclitaxel for mismatch repair deficient stage IIIC2 disease, with immune-related adverse event monitoring; universal Lynch syndrome tumor screening with MLH1 promoter methylation testing and genetic counseling; and survivorship care, on the NCCN uterine neoplasms guideline, the ACOG postmenopausal bleeding guidance, the SGO surveillance statement and the CMID endometrial cancer monograph.

Historical timeline

DateEventClaims
September 29, 1955Born in Queens, New York.CLM-0001
1977Graduates from Simmons College; hired by the Boston Herald American.CLM-0002
1999Becomes moderator of Washington Week in Review and a NewsHour senior correspondent.CLM-0003
2004Moderates the vice-presidential debate and asks about AIDS among Black women.CLM-0004
2009Publishes The Breakthrough.CLM-0004
2013Named co-anchor of the PBS NewsHour.CLM-0003
April 7, 2016Announces a leave of a few weeks for health reasons; returns by the start of June.CLM-0005
November 14, 2016Dies at a hospice in Washington, D.C., at 61; her family gives the cause as endometrial cancer, and friends describe a diagnosis at the turn of the year and treatment kept private.CLM-0006, CLM-0007

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Gwendolyn Ifill was born in Queens, New York, on September 29, 1955, the fifth of six children. Her father, a Panamanian immigrant, became a pastor in the African Methodist Episcopal Church; her mother was from Barbados. The family moved around the Northeast for her father's work and for a time lived in federally subsidized housing. confirmed Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports
HISTMED Master Roster v3 context
D She graduated from Simmons College in Boston in 1977. As a college intern at the Boston Herald American she found a racist note left for her; the paper's editors hired her after she graduated. She went on to report for the Baltimore Evening Sun, The Washington Post, The New York Times and NBC News.
Anchors the modern social history: a journalist who met racism early in her career and built one of the most respected careers in American news.
confirmed Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports
Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports
D In 1999 she became moderator of PBS's Washington Week in Review, the first African American woman to host a major national political talk show, and a senior correspondent for the NewsHour. In 2013 she and Judy Woodruff were named co-anchors of the PBS NewsHour, the first women to jointly lead a national nightly news broadcast.
Her work as an anchor and moderator anchors the modern social history.
confirmed Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports
Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Remembering Gwen supports
Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 supports
D She moderated the vice-presidential debates of 2004 and 2008. In the 2004 debate she asked the candidates about AIDS in the United States, citing the much higher death rate among Black women aged 25 to 44. She wrote The Breakthrough: Politics and Race in the Age of Obama (2009).
Her question in the 2004 debate drew national attention to a health disparity affecting Black women; the modern episode teaches another one.
confirmed Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports
Remembering Gwen supports
D On April 7, 2016, she told viewers she would be off the air for a few weeks; PBS described the reason as health issues it did not specify, and in May said she was doing well and expected to return around Memorial Day. She was back on the air by the start of June, when she interviewed President Obama.
The first public sign of her illness, three months after the modern index visit. The illness itself was not named in public until her death.
confirmed PBS' Gwen Ifill, on leave, expected to return in 2 weeks (The Associated Press) supports
Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports
Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) context
D She kept her illness private. After her death a close friend said she had been diagnosed with cancer at the end of 2015 or early in 2016, had told family and friends, and that the April leave was due to complications of treatment; another friend described her keeping up her work through chemotherapy. PBS said she died after several months of cancer treatment.
The anchor for the modern episode. These are friends' accounts and an official statement given after her death; the stage, histology and treatment of her cancer were never made public.
probable Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports
Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 supports
Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports
D She took a second leave shortly before her death and died at a hospice in Washington, D.C., on November 14, 2016, at 61. Her family gave the cause as endometrial cancer.
The documented disease to which the synthetic diagnosis is linked. History only, stated without detail.
confirmed Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports
Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports
Remembering Gwen supports
Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked resolved confirmed active CLM-0006
S Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer active confirmed both_with_link CLM-0006, CLM-0007
S Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2ii active confirmed active
S Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) active confirmed active
S Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2) active confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-01-05 Hemoglobin [Mass/volume] in Blood 11.8 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-01-05 Leukocytes [#/volume] in Blood by Automated count 6.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-01-05 Platelets [#/volume] in Blood by Automated count 268 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-01-05 Creatinine [Mass/volume] in Serum or Plasma 0.82 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-01-05 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 82 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-01-05 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-01-05 Hemoglobin A1c/Hemoglobin.total in Blood 5.5%
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes
http://loinc.org · 4548-4
S 2026-01-05 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-01-20 Hemoglobin [Mass/volume] in Blood 12.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-01-20 Leukocytes [#/volume] in Blood by Automated count 6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-01-20 Neutrophils [#/volume] in Blood by Automated count 3.6 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-01-20 Platelets [#/volume] in Blood by Automated count 274 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-01-20 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-01-20 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-01-20 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-01-20 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 84 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-01-20 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-01-20 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-01-20 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-01-20 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-01-20 Cancer Ag 125 [Units/volume] in Serum or Plasma 28 U/mL
Reference <=35 U/mL
http://loinc.org · 10334-1
S 2026-01-20 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-01-20 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 http://loinc.org · 70274-6
S 2026-02-24 Hemoglobin [Mass/volume] in Blood 11.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-02-24 Leukocytes [#/volume] in Blood by Automated count 6.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-02-24 Neutrophils [#/volume] in Blood by Automated count 3.9 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-02-24 Platelets [#/volume] in Blood by Automated count 301 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-02-24 Creatinine [Mass/volume] in Serum or Plasma 0.78 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-02-24 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 87 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-24 Glucose [Mass/volume] in Serum or Plasma 92 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-24 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-02-24 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-02-24 Bilirubin.total [Mass/volume] in Serum or Plasma 0.4 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-02-24 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-02-24 Magnesium [Mass/volume] in Serum or Plasma 2 mg/dL
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-02-24 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-02-24 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-02-24 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-04-28 Hemoglobin [Mass/volume] in Blood 10.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-28 Leukocytes [#/volume] in Blood by Automated count 4.3 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-28 Neutrophils [#/volume] in Blood by Automated count 2.1 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-04-28 Platelets [#/volume] in Blood by Automated count 196 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-04-28 Creatinine [Mass/volume] in Serum or Plasma 0.81 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-04-28 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 83 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-28 Glucose [Mass/volume] in Serum or Plasma 97 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-04-28 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-04-28 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-04-28 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-04-28 Magnesium [Mass/volume] in Serum or Plasma 1.8 mg/dL
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-04-28 Thyrotropin [Units/volume] in Serum or Plasma 4.8 mIU/L (high)
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-04-28 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-04-28 Cortisol [Mass/volume] in Serum or Plasma 12.6 ug/dL
Reference Morning sample, drawn before 9 a.m.
http://loinc.org · 2143-6
S 2026-04-28 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-06-30 Hemoglobin [Mass/volume] in Blood 11.4 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-30 Leukocytes [#/volume] in Blood by Automated count 4.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-30 Neutrophils [#/volume] in Blood by Automated count 2.8 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-06-30 Platelets [#/volume] in Blood by Automated count 228 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-30 Creatinine [Mass/volume] in Serum or Plasma 0.84 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-06-30 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 80 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-06-30 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-06-30 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-06-30 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-06-30 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-06-30 Thyrotropin [Units/volume] in Serum or Plasma 11.8 mIU/L (high)
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-06-30 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 0.7 ng/dL (low)
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-06-30 Cortisol [Mass/volume] in Serum or Plasma 13.1 ug/dL
Reference Morning sample, drawn before 9 a.m.
http://loinc.org · 2143-6
S 2026-06-30 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-08-11 Thyrotropin [Units/volume] in Serum or Plasma 3.6 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-08-11 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-08-11 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-08-11 Glucose [Mass/volume] in Serum or Plasma 93 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-08-11 Cholesterol [Mass/volume] in Serum or Plasma 204 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-08-11 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 124 mg/dL
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 2026-08-11 Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-08-11 Triglyceride [Mass/volume] in Serum or Plasma 110 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-08-11 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-01-05Body height165 cm8302-2S
2026-01-05Body weight74.6 kg29463-7S
2026-01-05Body mass index (BMI) [Ratio]27.4 kg/m239156-5S
2026-01-05Systolic blood pressure128 mm[Hg]8480-6S
2026-01-05Diastolic blood pressure80 mm[Hg]8462-4S
2026-01-05Heart rate78 /min8867-4S
2026-01-05Respiratory rate16 /min9279-1S
2026-01-05Body temperature36.7 Cel8310-5S
2026-01-05Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-01-20Body height165 cm8302-2S
2026-01-20Body weight74.2 kg29463-7S
2026-01-20Body mass index (BMI) [Ratio]27.3 kg/m239156-5S
2026-01-20Systolic blood pressure132 mm[Hg]8480-6S
2026-01-20Diastolic blood pressure82 mm[Hg]8462-4S
2026-01-20Heart rate84 /min8867-4S
2026-01-20Respiratory rate16 /min9279-1S
2026-01-20Body temperature36.6 Cel8310-5S
2026-01-20Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-02-24Body height165 cm8302-2S
2026-02-24Body weight72.6 kg29463-7S
2026-02-24Body mass index (BMI) [Ratio]26.7 kg/m239156-5S
2026-02-24Systolic blood pressure124 mm[Hg]8480-6S
2026-02-24Diastolic blood pressure78 mm[Hg]8462-4S
2026-02-24Heart rate80 /min8867-4S
2026-02-24Respiratory rate16 /min9279-1S
2026-02-24Body temperature36.7 Cel8310-5S
2026-02-24Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-04-28Body height165 cm8302-2S
2026-04-28Body weight71.8 kg29463-7S
2026-04-28Body mass index (BMI) [Ratio]26.4 kg/m239156-5S
2026-04-28Systolic blood pressure120 mm[Hg]8480-6S
2026-04-28Diastolic blood pressure76 mm[Hg]8462-4S
2026-04-28Heart rate82 /min8867-4S
2026-04-28Respiratory rate16 /min9279-1S
2026-04-28Body temperature36.6 Cel8310-5S
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-30Body height165 cm8302-2S
2026-06-30Body weight72.4 kg29463-7S
2026-06-30Body mass index (BMI) [Ratio]26.6 kg/m239156-5S
2026-06-30Systolic blood pressure122 mm[Hg]8480-6S
2026-06-30Diastolic blood pressure78 mm[Hg]8462-4S
2026-06-30Heart rate64 /min8867-4S
2026-06-30Respiratory rate16 /min9279-1S
2026-06-30Body temperature36.4 Cel8310-5S
2026-06-30Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-11Body height165 cm8302-2S
2026-08-11Body weight73 kg29463-7S
2026-08-11Body mass index (BMI) [Ratio]26.8 kg/m239156-5S
2026-08-11Systolic blood pressure124 mm[Hg]8480-6S
2026-08-11Diastolic blood pressure78 mm[Hg]8462-4S
2026-08-11Heart rate70 /min8867-4S
2026-08-11Respiratory rate16 /min9279-1S
2026-08-11Body temperature36.6 Cel8310-5S
2026-08-11Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation2026-01-20completedBiopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks
Surgical staging within four weeks of diagnosis2026-02-24completedMinimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation
Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week2026-06-30completedSix cycles on schedule; CT shows no evidence of disease
Lynch syndrome tumor screening completed and explained before treatment starts2026-02-24completedMLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done
Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule2026-06-30completedHypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and corrected
PHQ-9 below 10 throughout treatment, with support she chooses2026-06-30completedPHQ-9 between 4 and 6

Interventions

InterventionStatusGuideline
Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is foundcompletedGL-NCCN-UTERINE-2026, GL-ACOG-PMB-2026
Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visitcompletedGL-ACOG-PMB-2026, GL-ACOG-CO734-2018, GL-DOLL-2020, GL-CLARKE-2022
Staging and molecular classification: CT of the chest, abdomen and pelvis; mismatch repair immunohistochemistry and p53 on the biopsy, with MLH1 promoter methylation testing for MLH1 loss and POLE sequencing on the surgical specimen; FIGO 2023 stage with the molecular class recordedcompletedGL-NCCN-UTERINE-2026, GL-FIGO-2023, GL-CMID-2026
Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, pelvic washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodescompletedGL-NCCN-UTERINE-2026
Lynch syndrome screening of the tumor for every endometrial cancer, with genetic counseling; germline testing if mismatch repair loss is not explained by MLH1 promoter methylation, and cascade testing offered to blood relatives only if a germline variant is foundcompletedGL-NCCN-UTERINE-2026, GL-ACOG-PB147, GL-CMID-2026
Dostarlimab 500 mg with carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, for mismatch repair deficient stage IIIC2 disease; hepatitis B, hepatitis C and HIV screening first; three-drug antiemetic prevention; blood counts, kidney function and magnesium before each cycle; TSH, free T4, liver tests, glucose and morning cortisol at baseline and before each cycle; neuropathy checks at each visitcompletedGL-NCCN-UTERINE-2026, GL-RUBY-2023, GL-JEMPERLI-LABEL, GL-ASCO-IRAE-2021, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020, GL-CMID-2026
Immune-related hypothyroidism: levothyroxine with TSH and free T4 every six weeks, continuing dostarlimabcompletedGL-ASCO-IRAE-2021, GL-JEMPERLI-LABEL, GL-CMID-2026
Survivorship: examination with a pelvic examination every three months for two years, CT of the chest, abdomen and pelvis every six months for three years, no routine vaginal cytology and no CA-125 (normal at diagnosis), teaching on symptoms of recurrence, lymphedema checks, sexual health, weight, activity, blood pressure, lipid and glucose care, distress screening, and age-appropriate screening for other cancerscompletedGL-SGO-SURV-2026, GL-NCCN-UTERINE-2026, GL-CMID-2026
Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each notecompletedGL-USPSTF-DEP-2023, GL-NCCN-UTERINE-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) Anchorage Daily News other
SRC-0002 Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) KSL.com other
SRC-0003 Remembering Gwen PBS NewsHour other
SRC-0004 Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) NPR other
SRC-0005 Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 CBS News other
SRC-0006 PBS' Gwen Ifill, on leave, expected to return in 2 weeks (The Associated Press) InfoNews other
SRC-0007 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the combined biopsy and ultrasound pathway, the FIGO 2023 stage IIIC2ii with the MMRd molecular class, the choice of dostarlimab with carboplatin and paclitaxel, MLH1 methylation instead of germline testing, the immune-related hypothyroidism managed without stopping dostarlimab, and the survivorship schedule.
provenance reviewnot_startedRecent-death rule: only what she made public, what was reported during her life, and obituaries and official statements: The Washington Post, CNN, PBS NewsHour, NPR, CBS News and the Associated Press. The stage, histology and treatment of her cancer were never made public; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named in the modern episode, and no health fact, decision or genetic result is attributed to any real person.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.